What procedures does ROSA do?

Per Agent A orthopedic ingest, ROSA operates cross-domain multi-procedure scope spanning orthopedics + neurosurgery: knee orthopedic procedures + hip (direct-anterior) procedures + brain (stereoelectroencephalography SEEG + deep brain stimulation DBS) neurosurgical procedures + shoulder procedures. Per DEPLOY's framework, the cross-domain scope is editorially distinct: ROSA spans clinical domains that other orthopedic-sub-cohort entries do NOT cover. Mako is multi-procedure orthopedic + spine + shoulder but does NOT extend into neurosurgery; CORI is knee-only robotic.

Does ROSA do spine surgery?

No, ROSA Spine LEFT Zimmer Biomet in the 2022 ZimVie spinoff per Agent A orthopedic ingest CRITICAL CORRECTION. ROSA Spine is NOT a current Zimmer Biomet variant. ZimVie spinoff 2022: Zimmer Biomet spun off its dental + spine businesses as ZimVie Inc. (NASDAQ: ZIMV). ROSA Spine to ZimVie: the ROSA Spine product line transferred to ZimVie in the spinoff. Current ZB ROSA scope: knee + hip + brain + shoulder. NOT spine. Per cap-flag-as-trust-signal, trade-press coverage listing ROSA Spine as a current Zimmer Biomet variant operates outside Agent A primary-source-anchored verification.

No, ROSA operates AI-augmented surgeon-controlled assistance, NOT autonomous-robotic surgery per Agent A orthopedic ingest + DEPLOY's surgical cluster framework. Same assistive class as Stryker Mako + Smith+Nephew CORI + Intuitive da Vinci + Moon Surgical Maestro. CRITICAL CORRECTION per Agent A: Zimmer Biomet's autonomy positioning enters via a SEPARATE Monogram acquisition, NOT ROSA. The Monogram acquisition + ROSA platform are kept distinct in the entity record so the AI-augmented-not-autonomous framing holds across the orthopedic sub-cohort consistently.

What's the difference between ROSA, Mako, and CORI?

Architecture + procedure scope + parent company differ across the three Wave 3 orthopedic sub-cohort anchors. Zimmer Biomet ROSA: mid-size multi-procedure platform; cross-domain orthopedic + neurosurgery (knee + hip + brain + shoulder); ZB NYSE: ZBH. Stryker Mako: large-footprint CT-based robotic arm; multi-procedure orthopedic + spine + shoulder (knee + hip + spine K241517 + shoulder K242373); Stryker NYSE: SYK Portage MI. Smith+Nephew CORI: handheld imageless robotic system; knee-only robotic (hip is NAVIGATION-ONLY NOT robotic per Agent A); Smith+Nephew LSE: SN / NYSE: SNN. Per DEPLOY's surgical cluster framework, the three together anchor the Wave 3 orthopedic sub-cohort triangle's form-factor + procedure-scope variance axis.

Explainers Surgical robotics

What is Zimmer Biomet ROSA?

Zimmer Biomet ROSA (Robotic Surgical Assistant) is a mid-size cross-domain multi-procedure surgical robotic platform from Zimmer Biomet Holdings (NYSE: ZBH). Per Agent A orthopedic ingest: cleared for knee + hip (direct-anterior) + brain (SEEG/DBS) + shoulder; ROSA brain technology came via Medtech SA acquisition 2016 + subsequent extension to orthopedics. CRITICAL CORRECTIONS per Agent A: (1) ROSA Spine LEFT Zimmer Biomet in the 2022 ZimVie spinoff (NOT a current ZB variant); (2) ZB autonomy enters via SEPARATE Monogram acquisition, NOT ROSA (kept distinct so AI-augmented-not-autonomous framing holds across the orthopedic sub-cohort consistently). AI-augmented surgeon-controlled assistance (same assistive class as Mako + CORI + da Vinci + Maestro). Cohort positioning: mid-size cross-domain multi-procedure platform spanning orthopedics + neurosurgery within the Wave 3 orthopedic sub-cohort triangle.

NYSE: ZBH

Zimmer Biomet Holdings public company parent

Knee + hip + brain + shoulder

Cross-domain procedure scope (orthopedic + neurosurgery)

Medtech SA acquired 2016

Brain-technology origin; subsequent orthopedic extension

ROSA Spine LEFT ZB (2022 ZimVie)

NOT current ZB variant; correction per Agent A

Monogram separate from ROSA

Autonomy via separate acquisition; AI-augmented framing preserved

Mid-2026

Snapshot date

Tier legend:VerifiedAbsence

Cross-domain multi-procedure scope: knee + hip + brain + shoulder

Per Agent A orthopedic ingest, ROSA operates cross-domain multi-procedure scope spanning orthopedics + neurosurgery. Knee: orthopedic knee procedures. Hip (direct-anterior): hip procedures via direct-anterior surgical approach. Brain (SEEG/DBS): stereoelectroencephalography + deep brain stimulation neurosurgical procedures. Shoulder: shoulder procedures. Per DEPLOY's framework, the cross-domain (orthopedic + neurosurgery) procedure scope is editorially significant: ROSA spans clinical domains that other orthopedic-sub-cohort entries do NOT cover. Mako is multi-procedure orthopedic + spine + shoulder but does NOT extend into neurosurgery; CORI is knee-only robotic. The cross-domain extension into brain + DBS is a structurally distinct cohort-tier-specialization position.

CRITICAL CORRECTION #2: ZB autonomy enters via SEPARATE Monogram acquisition, NOT ROSA

Per Agent A orthopedic ingest, Zimmer Biomet's autonomy positioning enters via a SEPARATE Monogram acquisition, NOT ROSA. The Monogram acquisition + ROSA platform are kept distinct in the entity record so the AI-augmented-not-autonomous framing holds across the orthopedic sub-cohort consistently. ROSA (current scope): AI-augmented surgeon-controlled assistance; same assistive class as Mako + CORI + da Vinci + Maestro. Monogram (separate): autonomous-TKA technology entering ZB via separate acquisition; tracked as future-ingest candidate per Agent A flag. Per DEPLOY's framework, collapsing Monogram autonomy into the ROSA entity record would break the AI-augmented-not-autonomous framing applied consistently across all orthopedic-robotic anchors.

Acquisition lineage: Medtech SA 2016 (brain technology) + subsequent orthopedic extension

Per Agent A orthopedic ingest, the ROSA lineage operates through Medtech SA acquired 2016: Zimmer Biomet acquired Medtech SA, integrating ROSA brain technology (SEEG + DBS neurosurgical-robotic). Subsequent orthopedic extension: ROSA was extended from brain-only to orthopedic procedures (knee + hip + shoulder) via subsequent product development. Per DEPLOY's framework, the brain-technology-first lineage matters editorially at the entity verification layer: ROSA's orthopedic positioning is an extension of the original neurosurgical-robotic platform, not the inverse. Trade-press coverage framing ROSA as a Zimmer-Biomet-native orthopedic-robotic platform without the Medtech SA + brain-technology origin operates outside Agent A primary-source-anchored verification.

Zimmer Biomet ROSA: mid-size cross-domain multi-procedure archetype

Zimmer Biomet ROSA (Robotic Surgical Assistant) is a mid-size cross-domain multi-procedure surgical robotic platform from Zimmer Biomet Holdings (NYSE: ZBH). Per DEPLOY's surgical cluster framework, ROSA anchors the mid-size cross-domain multi-procedure platform archetype within the surgical cluster's Wave 3 orthopedic sub-cohort triangle alongside Stryker Mako (large-footprint CT-based) and Smith+Nephew CORI (handheld imageless).

Zimmer Biomet Holdings: NYSE: ZBH

Zimmer Biomet Holdings is a publicly-traded medical-technology company (NYSE: ZBH) with substantial orthopedic + dental + extremities + sports-medicine product portfolios. ROSA operates as Zimmer Biomet's surgical-robotic platform extending across orthopedic + neurosurgical clinical domains.

Cross-domain procedure scope: knee + hip + brain + shoulder

Per Agent A orthopedic ingest, ROSA operates cross-domain multi-procedure scope spanning orthopedics + neurosurgery:

Knee: orthopedic knee procedures (foundational orthopedic indication).
Hip (direct-anterior): hip procedures via direct-anterior surgical approach.
Brain (SEEG/DBS): stereoelectroencephalography (SEEG) + deep brain stimulation (DBS) neurosurgical procedures.
Shoulder: shoulder procedures.

Per DEPLOY's framework, the cross-domain (orthopedic + neurosurgery) procedure scope is editorially significant: ROSA spans clinical domains that other orthopedic-sub-cohort entries do NOT cover. Stryker Mako is multi-procedure orthopedic + spine + shoulder but does NOT extend into neurosurgery; Smith+Nephew CORI is knee-only robotic (hip navigation-only). The ROSA cross-domain extension into brain + spine-DBS represents a structurally distinct cohort-tier-specialization position.

Acquisition lineage: Medtech SA 2016 (brain technology) + subsequent orthopedic extension

Per Agent A orthopedic ingest, the ROSA lineage operates through:

Medtech SA acquired 2016: Zimmer Biomet acquired Medtech SA, integrating ROSA brain technology (SEEG + DBS neurosurgical-robotic).
Subsequent orthopedic extension: ROSA was extended from brain-only to orthopedic procedures (knee + hip + shoulder) via subsequent product development.

Per DEPLOY's framework, the brain-technology-first lineage matters editorially at the entity verification layer: ROSA's orthopedic positioning is an extension of the original neurosurgical-robotic platform, not the inverse. Trade-press coverage framing ROSA as a Zimmer-Biomet-native orthopedic-robotic platform without the Medtech SA + brain-technology origin operates outside Agent A primary-source-anchored verification.

CRITICAL CORRECTION #1: ROSA Spine LEFT Zimmer Biomet in 2022 ZimVie spinoff

Per Agent A orthopedic ingest, ROSA Spine LEFT Zimmer Biomet in the 2022 ZimVie spinoff. ROSA Spine is NOT a current Zimmer Biomet variant. Per DEPLOY's framework, the spinoff correction matters editorially:

ZimVie spinoff 2022: Zimmer Biomet spun off its dental + spine businesses as ZimVie Inc. (NASDAQ: ZIMV).
ROSA Spine to ZimVie: the ROSA Spine product line transferred to ZimVie in the spinoff.
Current ZB ROSA scope: knee + hip + brain + shoulder. NOT spine.

Per cap-flag-as-trust-signal, trade-press coverage listing ROSA Spine as a current Zimmer Biomet variant operates outside Agent A primary-source-anchored verification. The 2022 ZimVie spinoff transferred ROSA Spine out of the Zimmer Biomet portfolio; News Pub should NOT surface ROSA Spine as a current ZB product per Agent A.

CRITICAL CORRECTION #2: ZB autonomy enters via SEPARATE Monogram acquisition, NOT ROSA

ROSA (current scope): AI-augmented surgeon-controlled assistance; same assistive class as Mako + CORI + Intuitive da Vinci + Moon Maestro.
Monogram (separate): autonomous-TKA technology entering ZB via separate acquisition; tracked as future-ingest candidate per Agent A flag.

Per DEPLOY's framework, the keep-distinct framing is critical at the cohort verification posture layer: collapsing Monogram autonomy into the ROSA entity record would break the AI-augmented-not-autonomous framing applied consistently across all orthopedic-robotic anchors. Per cap-flag-as-trust-signal, the entity-scope discipline preserves cohort-framework boundary.

AI-augmented surgeon-controlled assistance (NOT autonomous); same class across cohort

Per Agent A orthopedic ingest + DEPLOY's surgical cluster framework, ROSA operates AI-augmented surgeon-controlled assistance, NOT autonomous-robotic surgery: same assistive class as Mako + CORI + Intuitive da Vinci + Moon Maestro. The AI-augmented-not-autonomous framing is applied consistently across the orthopedic sub-cohort triangle (Mako + CORI + ROSA) + broader surgical cluster (+ da Vinci + Maestro + Versius + Ottava).

Per DEPLOY's framework, the consistent framing matters editorially: trade-press coverage framing orthopedic-robotic systems as "autonomous surgical robots" operates outside Agent A primary-source-anchored verification. The Monogram autonomous-TKA technology operates separately + is tracked as future-ingest candidate; ROSA itself remains AI-augmented surgeon-controlled assistance.

Cap-flag: aggregator-installed-base figures conflict

Per cap-flag-as-trust-signal, aggregator-installed-base figures conflict for ROSA across trade-press coverage. Per DEPLOY's framework, specific installed-base counts operate at lower verification posture pending Zimmer Biomet SEC-disclosed primary-source confirmation; the cross-domain multi-procedure clinical scope is the load-bearing verified scope; specific installed-base + per-procedure deployment figures cap-flagged.

Cohort positioning: mid-size cross-domain multi-procedure platform archetype

Per the surgical cluster framework, Zimmer Biomet ROSA anchors:

Mid-size cross-domain multi-procedure platform archetype: knee + hip + brain + shoulder; spans orthopedics + neurosurgery.
Wave 3 orthopedic sub-cohort triangle: Mako (large-footprint CT-based) + CORI (handheld imageless) + ROSA (mid-size cross-domain); form-factor + procedure-scope variance axis.
Two critical corrections preserve cohort verification posture: ROSA Spine NOT current ZB (ZimVie 2022 spinoff); Monogram autonomy separate from ROSA.
Medtech SA 2016 brain-technology origin + subsequent orthopedic extension: brain-tech-first lineage editorially significant.
AI-augmented-surgeon-controlled-not-autonomous: consistent framing across orthopedic sub-cohort + broader surgical cluster.

Contrast with cohort:

Stryker Mako: large-footprint CT-based; multi-procedure orthopedic + spine + shoulder; market-leader positioning.
Smith+Nephew CORI: handheld imageless; knee-only robotic (hip is navigation-only NOT robotic).
Intuitive da Vinci: replacement-robotics soft-tissue market-leader.
Moon Surgical Maestro: assistive-laparoscopy commercial-niche.
CMR Versius: international commercial soft-tissue modular architecture.

Consumer pricing surface for Zimmer Biomet ROSA is forthcoming via Agent B's planned orthopedic sub-cohort /price triangle; per cap-flag-as-trust-signal, the consumer-price-page is documented as forthcoming honest-absence pending Agent B's ship. Registry institutional depth at Zimmer Biomet registry company + ROSA registry model.

For the canonical surgical cluster context, see the surgical robotics cluster. For the large-footprint orthopedic contrast, see what is Stryker Mako. For the handheld imageless contrast, see what is Smith+Nephew CORI. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Zimmer Biomet ROSA: the 4-way autonomy-boundary taxonomy (AI-augmented operator-controlled tier; mid-size cross-domain) + verified-vs-claimed at within-entity granularity (per-procedure clearances across knee + hip + brain SEEG/DBS + shoulder; CRITICAL CORRECTION ROSA Spine LEFT ZB in 2022 ZimVie spinoff) + the 9-tier source-quality rubric (FDA + ZB SEC source classification).

Source: DEPLOY registry + Agent A orthopedic ingest + Zimmer Biomet SEC filings + FDA 510(k) database verification. Surgical cohort orthopedic sub-cohort form-factor + procedure-scope + parent-company framework.
Entity	Form-factor	Procedure scope	Parent company
Zimmer Biomet ROSA	Mid-size multi-procedure platform	Knee + hip (direct-anterior) + brain (SEEG/DBS) + shoulder; cross-domain ortho + neurosurgery	Zimmer Biomet (NYSE: ZBH)
Stryker Mako	Large-footprint CT-based robotic arm	Multi-procedure: knee + hip + spine (K241517) + shoulder (K242373)	Stryker (NYSE: SYK)
Smith+Nephew CORI	Handheld imageless robotic system	Knee-only ROBOTIC; hip is NAVIGATION-ONLY (NOT robotic)	Smith+Nephew (LSE: SN / NYSE: SNN)
Intuitive da Vinci	Replacement-robotics monolithic console	Multi-procedure soft-tissue (vs orthopedic-bone)	Intuitive Surgical (NASDAQ: ISRG)
Moon Surgical Maestro	Assistive laparoscopy co-pilot	ASSISTIVE laparoscopy (NOT replacement)	Moon Surgical (French-US dual)
CMR Versius	Replacement-robotics modular soft-tissue	Soft-tissue surgical (EU + UK + Australia + India commercial)	CMR Surgical (UK; Cambridge)

Frequently asked questions

What is Zimmer Biomet ROSA?: Zimmer Biomet ROSA (Robotic Surgical Assistant) is a mid-size cross-domain multi-procedure surgical robotic platform from Zimmer Biomet Holdings (NYSE: ZBH). Per Agent A orthopedic ingest: cleared for knee + hip (direct-anterior) + brain (SEEG/DBS) + shoulder; ROSA brain technology came via Medtech SA acquisition 2016 + subsequent extension to orthopedics. Per DEPLOY's surgical cluster framework, ROSA anchors the mid-size cross-domain multi-procedure platform archetype within the Wave 3 orthopedic sub-cohort triangle alongside Stryker Mako (large-footprint CT-based) and Smith+Nephew CORI (handheld imageless).
What procedures does ROSA do?: Per Agent A orthopedic ingest, ROSA operates cross-domain multi-procedure scope spanning orthopedics + neurosurgery: knee orthopedic procedures + hip (direct-anterior) procedures + brain (stereoelectroencephalography SEEG + deep brain stimulation DBS) neurosurgical procedures + shoulder procedures. Per DEPLOY's framework, the cross-domain scope is editorially distinct: ROSA spans clinical domains that other orthopedic-sub-cohort entries do NOT cover. Mako is multi-procedure orthopedic + spine + shoulder but does NOT extend into neurosurgery; CORI is knee-only robotic.
Does ROSA do spine surgery?: No, ROSA Spine LEFT Zimmer Biomet in the 2022 ZimVie spinoff per Agent A orthopedic ingest CRITICAL CORRECTION. ROSA Spine is NOT a current Zimmer Biomet variant. ZimVie spinoff 2022: Zimmer Biomet spun off its dental + spine businesses as ZimVie Inc. (NASDAQ: ZIMV). ROSA Spine to ZimVie: the ROSA Spine product line transferred to ZimVie in the spinoff. Current ZB ROSA scope: knee + hip + brain + shoulder. NOT spine. Per cap-flag-as-trust-signal, trade-press coverage listing ROSA Spine as a current Zimmer Biomet variant operates outside Agent A primary-source-anchored verification.
Is ROSA autonomous?: No, ROSA operates AI-augmented surgeon-controlled assistance, NOT autonomous-robotic surgery per Agent A orthopedic ingest + DEPLOY's surgical cluster framework. Same assistive class as Stryker Mako + Smith+Nephew CORI + Intuitive da Vinci + Moon Surgical Maestro. CRITICAL CORRECTION per Agent A: Zimmer Biomet's autonomy positioning enters via a SEPARATE Monogram acquisition, NOT ROSA. The Monogram acquisition + ROSA platform are kept distinct in the entity record so the AI-augmented-not-autonomous framing holds across the orthopedic sub-cohort consistently.
When did Zimmer Biomet get ROSA?: Per Agent A orthopedic ingest, the ROSA lineage operates through Medtech SA acquired 2016: Zimmer Biomet acquired Medtech SA, integrating ROSA brain technology (SEEG + DBS neurosurgical-robotic). Subsequent orthopedic extension: ROSA was extended from brain-only to orthopedic procedures (knee + hip + shoulder) via subsequent product development. Per DEPLOY's framework, the brain-technology-first lineage matters editorially at the entity verification layer: ROSA's orthopedic positioning is an extension of the original neurosurgical-robotic platform, not the inverse.
What's the difference between ROSA, Mako, and CORI?: Architecture + procedure scope + parent company differ across the three Wave 3 orthopedic sub-cohort anchors. Zimmer Biomet ROSA: mid-size multi-procedure platform; cross-domain orthopedic + neurosurgery (knee + hip + brain + shoulder); ZB NYSE: ZBH. Stryker Mako: large-footprint CT-based robotic arm; multi-procedure orthopedic + spine + shoulder (knee + hip + spine K241517 + shoulder K242373); Stryker NYSE: SYK Portage MI. Smith+Nephew CORI: handheld imageless robotic system; knee-only robotic (hip is NAVIGATION-ONLY NOT robotic per Agent A); Smith+Nephew LSE: SN / NYSE: SNN. Per DEPLOY's surgical cluster framework, the three together anchor the Wave 3 orthopedic sub-cohort triangle's form-factor + procedure-scope variance axis.

Zimmer Biomet ROSA verified as mid-size cross-domain multi-procedure platform archetype. Zimmer Biomet Holdings NYSE: ZBH. ROSA Robotic Surgical Assistant cleared for knee + hip (direct-anterior) + brain (SEEG/DBS) + shoulder; cross-domain orthopedic + neurosurgical scope. Acquisition lineage: Medtech SA acquired 2016 (brain technology origin) + subsequent orthopedic extension. CRITICAL CORRECTION #1: ROSA Spine LEFT Zimmer Biomet in 2022 ZimVie spinoff; NOT a current ZB variant; current ZB ROSA scope is knee + hip + brain + shoulder (NOT spine). CRITICAL CORRECTION #2: Zimmer Biomet autonomy positioning enters via SEPARATE Monogram acquisition NOT ROSA; kept distinct so AI-augmented-not-autonomous framing holds across the orthopedic sub-cohort consistently. AI-augmented surgeon-controlled assistance (NOT autonomous); same assistive class as Mako + CORI + da Vinci + Maestro. Aggregator-installed-base figures cap-flagged pending Zimmer Biomet SEC-disclosed primary-source confirmation. How DEPLOY verifies →

Compare alternatives

Zimmer Biomet registry companyZimmer Biomet ROSA registry modelStryker Mako comparison explainerSurgical robotics cluster

More in surgical robotics

View all 18 explainers in surgical robotics →

← All explainers

What is Zimmer Biomet ROSA?

Zimmer Biomet ROSA: mid-size cross-domain multi-procedure archetype

Zimmer Biomet Holdings: NYSE: ZBH

Cross-domain procedure scope: knee + hip + brain + shoulder

Acquisition lineage: Medtech SA 2016 (brain technology) + subsequent orthopedic extension

CRITICAL CORRECTION #1: ROSA Spine LEFT Zimmer Biomet in 2022 ZimVie spinoff

CRITICAL CORRECTION #2: ZB autonomy enters via SEPARATE Monogram acquisition, NOT ROSA

AI-augmented surgeon-controlled assistance (NOT autonomous); same class across cohort

Cap-flag: aggregator-installed-base figures conflict

Cohort positioning: mid-size cross-domain multi-procedure platform archetype

Frequently asked questions

Continue reading

What is Stryker Mako?

What is Smith+Nephew CORI?

What is Intuitive Surgical da Vinci?

The surgical robotics cluster

More in surgical robotics